A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Condition:   Hypercholesterolemia Interventions:   Drug: K-877 0.2 mg/day (once daily);   Drug: K-877 0.4 mg/day (once daily);   Drug: Placebo (once daily) Sponsor:   Kowa Company, Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials